NCT03622021View on ClinicalTrials.gov

A Study of AK111 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

September 9, 2019

Study Completion Date

September 9, 2019

Conditions
Psoriasis
Interventions
DRUG

AK111 or Placebo

All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.

Trial Locations (1)

8140

Christchurch Clinical Studies Trust (CCST), Christchurch

All Listed Sponsors
lead

Akesobio Australia Pty Ltd

INDUSTRY

NCT03622021 - A Study of AK111 in Healthy Subjects | Biotech Hunter | Biotech Hunter